Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (AURORA-1)

NCT07743463 is registered in ClinicalTrials.gov with Ascletis Pharma (China) Co., Limited as lead sponsor.

NCT NCT07743463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07743463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (AURORA-1)
Lead sponsor
Ascletis Pharma (China) Co., Limited
Phase
Phase 3
Overall status
Recruiting
Start date
August 31, 2026
Completion date
July 31, 2028
Enrollment
3,003 (estimated)
Sites
122

Conditions

As the registry lists them; a condition with its own page is linked.

chronic weight management, obesity, overweight